H. Lundbeck AS - Company Profile
Powered by
All the data and insights you need on H. Lundbeck AS in one report.
- Save hours of research time and resources with
our up-to-date H. Lundbeck AS Strategy Report
- Understand H. Lundbeck AS position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
H. Lundbeck AS (Lundbeck), a subsidiary of The Lundbeck Foundation, is a specialty pharmaceutical company, which discovers, develops, produces, and markets pharmaceuticals for the treatment of diseases of the central nervous system (CNS). Focuse on R&D activities, the performance of product candidate Brintellix/Trintellix, and a comprehensive CNS portfolio are its strengths even as increasing trade receivables could be a major cause for concern to the company. Lundbeck could benefit from the market potential for Alzheimer's Disease, regulatory approvals, and unique pipeline products. However, intense competition, uncertain R&D outcomes, and stringent government regulations could hinder the company's growth.
Strengths
Weaknesses
Opportunities
Threats
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer